Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab vedotin plus R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma
NL-OMON59425Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON59425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59425.